CT1812
Phase 2Small molecule
CT1812 is one of 49 small molecule programs targeting Dementia. It is currently in Phase 2.
1
Indications
10
Total Trials
1
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
138 competitors in Dementia
#DrugCompanyPhaseTrials
1Leqembi
EisaiPhase 3
Depacon
AbbViePhase 3
Abilify
OtsukaPhase 3
Glucophage
EMD SeronoPhase 3
MS Contin
HHikma Pharmaceuticals LLC
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Aricept
EisaiPhase 3
Seroquel
AstraZenecaPhase 3
Dayvigo
EisaiPhase 2
Aleve
Alnylam PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Mild to Moderate Alzheimer's Disease4 trials
Early Alzheimer's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CT1812. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCognition Therapeutics